MAIA Biotechnology, Inc. develops targeted immunotherapies for cancer, with news centered on its lead investigational therapy, ateganosine, also known as THIO, for non-small cell lung cancer. Company updates frequently address the THIO-101 clinical program, ateganosine’s telomere-targeting and immune-activating mechanism, use with the checkpoint inhibitor cemiplimab, and FDA Fast Track designation in third-line NSCLC.
Recurring MAIA news also includes oncology data presentations, shareholder letters on the development pipeline, clinical-site and trial-expansion updates, and financing activity tied to its clinical programs. Capital-market announcements have included common stock offerings, shelf registration use, and stated uses of proceeds for clinical trials, working capital, and general corporate purposes.
MAIA Biotechnology (NYSE: MAIA) has announced a private placement offering of 463,332 shares of common stock at $1.50 per share to accredited investors and a Company director. The offering includes warrants to purchase an equal number of shares at $1.71 per exercise price, exercisable after six months with a five-year term. The private placement is expected to close around May 29, 2025, with anticipated gross proceeds of approximately $695,000.
The company plans to use the proceeds to fund Step 1 of Part C of the Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act.
MAIA Biotechnology (NYSE: MAIA) announced the acceptance of their abstract for poster presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will showcase efficacy data from their Phase 2 THIO-101 clinical trial of ateganosine (THIO), a telomere targeting agent, in combination with cemiplimab for third-line immune checkpoint inhibitor-resistant advanced NSCLC.
The poster, titled "Phase 2 Study of Telomere-Targeting Agent THIO Sequenced With Cemiplimab in Third-Line Immune Checkpoint Inhibitor–Resistant Advanced NSCLC: Evaluation of Overall Survival," will be presented by Dr. Tomasz Jankowski on May 31, 2025, from 1:30 PM to 4:30 PM CDT in the Lung Cancer track. CEO Vlad Vitoc expressed confidence in ateganosine's potential to become a best-in-class anticancer treatment.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. The offering includes warrants to purchase one share of common stock at $2.05 per share, exercisable one year after issuance with a six-year term.
The private placement is expected to close around May 7, 2025. The proceeds will be used to fund the initiation of Part C of the Phase II THIO-101 trial and for working capital. Securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the Company's 2021 Equity Incentive Plan.
MAIA Biotechnology (NYSE: MAIA) has secured a $1.08 million private placement through the sale of 719,999 shares of common stock at $1.50 per share to accredited investors and company directors. Each share comes with a warrant to purchase one additional share at $2.05, exercisable after six months with a five-year term. The placement is expected to close around May 7, 2025.
The company plans to use the proceeds to fund the initiation of Part C of their Phase II THIO-101 trial and for working capital. The securities are being offered under Section 4(a)(2) of the Securities Act and Regulation D, with director purchases made through the company's 2021 Equity Incentive Plan.
MAIA Biotechnology (NYSE: MAIA) has outlined key clinical milestones for 2025 in a shareholder letter from CEO Vlad Vitoc. The company's lead compound THIO (ateganosine) is highlighted as the only clinical-stage telomere-targeting anticancer agent in cancer discovery.
Key developments include:
- Phase 2 trial THIO-101 expansion is ongoing with potential FDA filing for accelerated approval in 2026
- Phase 3 THIO-104 trial scheduled to begin mid-2025, with potential filing for early full approval in 2026
- THIO demonstrates exceptional efficacy in advanced non-small cell lung cancer (NSCLC)
- Multiple additional THIO trials planned for various cancer indications
The company is pursuing multiple regulatory pathways for THIO in NSCLC treatment, targeting significant market opportunities in hard-to-treat cancers with unmet medical needs.
MAIA Biotechnology (NYSE: MAIA) announced its selection to present a poster at the European Lung Cancer Congress 2025 (ELCC 2025) in Paris, France, from March 26-29. The presentation will focus on cytokine Interleukin-6 (IL-6) as a potential predictive biomarker for THIO treatment response in advanced non-small cell lung cancer (NSCLC).
The poster will highlight findings related to THIO's mechanisms of action when sequenced with checkpoint inhibitors, following exceptional efficacy demonstrated in the company's Phase 2 clinical trial. The ELCC, a program of the European Society for Medical Oncology (ESMO), brings together key multidisciplinary societies in thoracic oncology to advance science and improve lung cancer specialist practices.
MAIA Biotechnology (NYSE: MAIA) has published preclinical data in Naunyn-Schmiedeberg's Archives of Pharmacology regarding their novel THIO dimer compound. The study, published on February 15, 2025, demonstrates that THIO and its dimer form effectively inhibit Glutathione S-transferase Pi (GSTP1), an enzyme important in cancer progression and chemoresistance.
The research reveals the compound's potential dual mechanism of action for enhancing standard cancer treatments and addressing drug resistance. As part of MAIA's second-generation research platform, which has developed over 80 THIO-like compounds, this breakthrough aims to identify telomere-targeting compounds with improved cancer cell specificity and increased anticancer activity.
The findings suggest that the dimerized form of THIO could enhance chemotherapeutic efficacy through GSTP1 targeting, potentially offering new strategies for combating drug-resistant cancers.
MAIA Biotechnology (NYSE: MAIA) announced that the United States Adopted Names (USAN) Council has approved 'ateganosine' as the nonproprietary name for its lead molecule THIO, a telomere-targeting anticancer agent in development for advanced non-small cell lung cancer (NSCLC).
The USAN Council, comprising experts from the American Medical Association, U.S. Pharmacopeial Convention, and FDA, is responsible for selecting standardized generic drug names. The name ateganosine was chosen to reflect the drug's mechanism of action in altering telomeric guanosine of cancer cells.
This approval represents a significant milestone in MAIA's regulatory pathway as the company progresses with Phase 2 and 3 clinical trials. The company will continue using the name THIO in its clinical trial designations (THIO-101, THIO-102, THIO-103, THIO-104).